Next Article in Journal
Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold
Next Article in Special Issue
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
Previous Article in Journal
Antibody–Drug Conjugates for Cancer Therapy
Previous Article in Special Issue
Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
Article Menu

Export Article

Open AccessFeature PaperReview
Biomedicines 2016, 4(3), 16; doi:10.3390/biomedicines4030016

Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!

Immunological and Oncological Center (IOZK), Tumor Immunology, 50674 Cologne, Germany
Academic Editor: Zong Sheng Guo
Received: 22 June 2016 / Revised: 14 July 2016 / Accepted: 18 July 2016 / Published: 20 July 2016
(This article belongs to the Special Issue Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer)
View Full-Text   |   Download PDF [226 KB, uploaded 20 July 2016]   |  

Abstract

This review provides an overview of 50 years of basic and clinical research on an oncolytic avian virus, Newcastle Disease Virus (NDV), which has particular anti-neoplastic and immune stimulatory properties. Of special interest is the fact that this biological agent induces immunogenic cell death and systemic anti-tumor immunity. Furthermore, localized oncolytic virotherapy with NDV was shown to overcome systemic tumor resistance to immune checkpoint blockade immunotherapy. Clinical experience attests to low side effects and a high safety profile. This is due among others to the strong virus-induced type I interferon response. Other viral characteristics are lack of interaction with host cell DNA, lack of genetic recombination and independence of virus replication from cell proliferation. In this millennium, new recombinant strains of viruses are being produced with improved therapeutic properties. Clinical applications include single case observations, case series studies and Phase I to III studies. View Full-Text
Keywords: oncolysis; immunogenic cell death; dendritic cells; tumor vaccine; immune activation; virotherapy; immunotherapy oncolysis; immunogenic cell death; dendritic cells; tumor vaccine; immune activation; virotherapy; immunotherapy
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schirrmacher, V. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines 2016, 4, 16.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top